Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial

At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …

Axumin-based PET/CT scans and detection of recurrent prostate cancer

A new report from a relatively small, single-institution study has provided additional information about the utility of [18F]fluciclovine (Axumin) PET/CT scans in the detection of recurrent prostate cancer after definitive first-line treatment. … READ MORE …

Alas … PPV not good for PI-RADS at all

For the past few years, some of us have been quietly concerned about the true value of MRI scans and the accuracy of PI-RADS scores in evaluation of a patient’s risk for the presence of clinically significant prostate cancer. This is a complex issue … but data from a large, recently completed study has now validated these concerns. … READ MORE …

Jane Brody on prostate cancer in the NYT

Jane Brody is an experienced journalist who writes regularly about issues related to health care in The New York Times. Your sitemaster regularly reads her columns because she does her homework with care and provides sound information for her readers. … READ MORE …

Diabetes and risk for prostate cancer

There have long been suggestions that men already diagnosed with and receiving treatment for diabetes are at lower risk for a subsequent diagnosis of prostate cancer than non-diabetics. However, a very large, new, epidemiological analysis seems to suggest strongly that this may not be the case at all. … READ MORE …

Risk for prostate cancer in men under 40 years of age

A newly published paper by Blayer et al. in in the journal Cancer has stated that,

Worldwide, the incidence of prostate cancer has increased in all groups between ages 15 and 40 years and increased globally at a steady rate averaging 2% per year since 1990.

… READ MORE …

Risk for early onset prostate cancer MAY BE increased in some infertile men

In posting the following commentary, we wish to be VERY clear that, at this time, there is no definitive evidence that there is a causal relationship between male infertility and risk for prostate cancer, but this does appear to be a POSSIBILITY. … READ MORE …

The first-line treatment of locally advanced prostate cancer (clinical stage T3)

Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy (ADT) among patients initially diagnosed with locally advanced (T3) prostate cancer? … READ MORE …

The celebrity prostate cancer line-up … and what they actually say

What celebs say and don’t say about prostate cancer (if they say anything at all) has often been difficult for the average patient to understand — as are some of their apparent treatment decisions (if those are actually mentioned). … READ MORE …

Moving targets and the interpretation of “new” medical “knowledge”

In this week’s New England Journal of Medicine (NEJM), there is an interesting article entitled, “Contingent knowledge and looping effects — a 66-year-old man with PSA-detected prostate cancer and regrets”. … READ MORE …

Complementary and alternative medicines in management of prostate cancer

A newly published paper in the Journal of Urology has reported on the use of complementary and alternative medicines (CAMs) among a cohort of nearly 8,000 American patients with a diagnosis of prostate cancer between 1996 and 2016. … READ MORE …

PCaI extends low-cost room rate for conference in Virginia Beach

Prostate Cancer International (PCaI) has been able extend the hotel discount deadline to Monday, Oct 7th for its FREE patient conference in Virginia Beach on November 2. … READ MORE …

Does eating mushrooms prevent prostate cancer?

Well, maybe, … at least among men living in in the Miyagi and Ohsaki prefectures, in Japan. … READ MORE …

The APCCC in Basel, Switzerland: Day 1

So in this series of reports on what happened at the 3rd Advanced Prostate Cancer Consensus Conference (APCCC) in Basel, Switzerland, we will not be trying to get into detail about exactly what data got presented each day. … READ MORE …

FDA approves new technique for “ablation of prostate tissue”

According to a media release issued by a Canadian company called Profound Medical on August 16, the US Food and Drug Administration (FDA) has approved the use of a system called TULSA-PRO for the “ablation of prostate tissue”. There appears to be no relevant information on the FDA web site — as yet. … READ MORE …